• 1. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 2. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-arylpiperazines

Introduction to 3-methyl-6-(piperazin-1-yl)pyridazine (CAS No: 219635-87-7)

3-methyl-6-(piperazin-1-yl)pyridazine, identified by the Chemical Abstracts Service Number (CAS No) 219635-87-7, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical research and drug development. This compound belongs to the pyridazine class, characterized by a six-membered ring containing two adjacent nitrogen atoms. The presence of a methyl group at the 3-position and a piperazine moiety at the 6-position introduces unique structural and chemical properties, making it a versatile scaffold for medicinal chemistry applications.

The piperazin-1-yl substituent is particularly noteworthy due to its prevalence in bioactive molecules. Piperazine derivatives are known for their ability to interact with biological targets such as enzymes and receptors, often leading to favorable pharmacokinetic profiles. In particular, the nitrogen atoms in piperazine can form hydrogen bonds, enhancing binding affinity and selectivity. This feature has been leveraged in the design of drugs targeting various therapeutic areas, including central nervous system disorders, infectious diseases, and oncology.

Recent advancements in computational chemistry and molecular modeling have facilitated the exploration of 3-methyl-6-(piperazin-1-yl)pyridazine as a potential lead compound. Studies have demonstrated that modifications to the pyridazine core, such as the introduction of electron-withdrawing or electron-donating groups, can significantly alter its biological activity. For instance, computational studies suggest that this compound may exhibit inhibitory effects on certain kinases and transcription factors, which are implicated in cancer progression.

One of the most compelling aspects of 3-methyl-6-(piperazin-1-yl)pyridazine is its potential as a building block for more complex drug candidates. By incorporating additional functional groups or appending different pharmacophores, researchers can generate libraries of derivatives with tailored properties. High-throughput screening (HTS) and structure-based drug design (SBDD) approaches have been employed to identify promising analogs. These methodologies leverage the structural flexibility of the pyridazine-piperazine scaffold to optimize potency, selectivity, and metabolic stability.

In vitro studies have provided preliminary insights into the pharmacological profile of 3-methyl-6-(piperazin-1-yl)pyridazine. Initial assays indicate that this compound may possess anti-inflammatory and analgesic properties, making it a candidate for treating chronic pain conditions or inflammatory diseases. Furthermore, its interaction with membrane-bound receptors has been explored using molecular dynamics simulations, revealing potential binding modes that could inform future drug design efforts.

The synthesis of 3-methyl-6-(piperazin-1-yl)pyridazine involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions between appropriately substituted pyridazine precursors with piperazine derivatives. Advances in catalytic methods have enabled more efficient and sustainable synthetic pathways, reducing waste and improving scalability.

Regulatory considerations play a crucial role in the development of novel compounds like 3-methyl-6-(piperazin-1-yl)pyridazine. Compliance with Good Manufacturing Practices (GMP) and adherence to safety guidelines are essential for advancing preclinical and clinical studies. Collaborative efforts between academic institutions and pharmaceutical companies have accelerated the translation of laboratory findings into clinical candidates, leveraging expertise in synthetic chemistry, pharmacology, and toxicology.

The future prospects for 3-methyl-6-(piperazin-1-yl)pyridazine are promising, given its structural features and biological potential. Ongoing research aims to elucidate its mechanism of action and explore its efficacy in animal models of disease. As our understanding of target biology evolves, so too will our ability to rationally design molecules that modulate these pathways effectively. The integration of artificial intelligence (AI) into drug discovery pipelines is expected to further enhance the development process, identifying novel derivatives with improved therapeutic profiles.

In conclusion,3-methyl-6-(piperazin-1-yl)pyridazine (CAS No: 219635-87-7) represents a significant asset in medicinal chemistry research. Its unique structural features combined with its demonstrated biological activity make it a valuable scaffold for developing new therapeutic agents. As research progresses, this compound is likely to contribute to advancements across multiple therapeutic areas, offering hope for improved treatments for a variety of human diseases.

• 64224-54-0(3-Pyridazinecarbonitrile, 6-(4-methyl-1-piperazinyl)-)
• 1420898-48-1(1-(6-Methylpyridazin-3-yl)-1,4-diazepane hydrochloride)
• 66346-94-9(6-(4-Methylpiperazin-1-yl)pyridazin-3-amine)
• 223797-15-7(1-(6-Methylpyridazin-3-yl)-1,4-diazepane)
• 682779-97-1(3-(4-Ethyl-1-piperazinyl)-6-methylpyridazine)
• 223796-10-9(4-Methyl-1-(6-methyl-3-pyridazinyl)-homopiperazine)
• 1420899-87-1(3-Methyl-6-(3-methylpiperazin-1-yl)pyridazine hydrochloride)
• 1232082-73-3(6-(1-piperazinyl)-3-Pyridazinamine)
• 1420810-68-9(3-Methyl-6-(2-methylpiperazin-1-yl)pyridazine hydrochloride)
• 926232-26-0(1-methyl-4-(piperazin-1-yl)phthalazine)